The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
Top Cited Papers
Open Access
- 10 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-15
- https://doi.org/10.1038/s41392-020-0187-x
Abstract
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafenib is becoming increasingly common. This study aims to identify factors contributing to resistance and ways to mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated cell death, and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients.Keywords
This publication has 173 references indexed in Scilit:
- The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib ResistancePLOS ONE, 2013
- Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment in vivoActa Radiologica, 2013
- Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular CarcinomaPLOS ONE, 2013
- Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cellsCell Death & Disease, 2013
- The kinase inhibitor Sorafenib impairs the antiviral effect of interferon α on hepatitis C virus replicationEuropean Journal of Cell Biology, 2013
- Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinomaBritish Journal of Cancer, 2012
- The Double-Edged Sword of Autophagy Modulation in CancerClinical Cancer Research, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Autophagy: process and functionGenes & Development, 2007
- Autophagy in Health and Disease: A Double-Edged SwordScience, 2004